Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailL'infusion chronique et centrale d'ocytocine améliore la résistance à l'insuline induite par une nourriture riche en lipides chez le rat
Deblon, Nicolas; Veyrat-Durebex, Christelle; Legros, Jean-Jacques ULg et al

Conference (2011, March 23)

Detailed reference viewed: 32 (1 ULg)
Full Text
Peer Reviewed
See detailInfusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease
Hannon, Muriel ULg; LECHANTEUR, Chantal ULg; Lucas, Sophie et al

in Transfusion (2014), 54(February), 353-363

Detailed reference viewed: 81 (36 ULg)
Full Text
See detailInfusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease
Hannon, Muriel ULg; Lechanteur, C.; Somja, Joan ULg et al

in Belgian Journal of Hematology (2013), Abstracts book(Supplement of 28th General Meeting of the Belgian Hematological Society), 15

Detailed reference viewed: 23 (9 ULg)
Full Text
Peer Reviewed
See detailInfusion of third party mesenchymal stem cells (MSC) after kidney and liver transplantation: a phase I-II, open-label, clinical study
DETRY, Olivier ULg; DELBOUILLE, Marie-Hélène ULg; LECHANTEUR, Chantal ULg et al

Conference (2012, October 19)

MSC cells have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aims to be the first evaluation of the safety and tolerability of third party MSC ... [more ▼]

MSC cells have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aims to be the first evaluation of the safety and tolerability of third party MSC infusion after cadaveric kidney and liver transplantation in a prospective phase I-II study, taking advantage of our centre expertise and experience in MSC use in graft-versus-host disease (GVHD) after bone marrow transplantation and using an already functioning GMP-compliant laboratory producing clinical-grade MSC. Secondary end-points will help to evaluate the immunosuppressive potential of MSC after organ transplantation, and the opportunity to develop larger randomised, controlled, phase III trials. After successful transplantation, 10 liver and 10 kidney transplant recipients under standard immunosuppression (tacrolimus, MMF, steroids) will receive an intravenous infusion of 1.5-3x106/kg of third-party MSC on post-operative day 3±2. These patients will be prospectively compared to 10 liver and 10 kidney recipients who meet the inclusion criteria but deny MSC infusion. Safety will be assessed by recording side effects, including opportunistic infections and cancers. Immunosuppressive potential will be evaluated by rejection episode rates, by graft/patient survivals, by immunohistology of 3-months kidney and 6-month liver graft biopsies and by in vitro evaluation of the immunity profile of the recipients. In a second step, reduction (kidney) and progressive weaning (liver) of immunosuppression will be attempted in recipients who received MSC. This ongoing study is supported by research grants from the CHU of Liège, University of Liège, and by the Senior Clinical Research Grant from ESOT. The first patients were included and treated in early 2012, and final results expected in late 2013. [less ▲]

Detailed reference viewed: 91 (10 ULg)
Full Text
Peer Reviewed
See detailINFUSION OF THIRD-PARTY MESENCHYMAL STEM CELLS (MSC) AFTER KIDNEY AND LIVER TRANSPLANTATION: A PHASE I-II, OPEN-LABEL, CLINICAL STUDY (EudraCT 2011-001822-81 & NCT01429038)
DETRY, Olivier ULg; DELBOUILLE, Marie-Hélène ULg; LECHANTEUR, Chantal ULg et al

Poster (2013, May 30)

MSC cells have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aims to be the first evaluation of the safety and tolerability of third party MSC ... [more ▼]

MSC cells have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aims to be the first evaluation of the safety and tolerability of third party MSC infusion after cadaveric kidney and liver transplantation in a prospective phase I-II study, taking advantage of our centre expertise and experience in MSC use in graft-versus-host disease (GVHD) after bone marrow transplantation and using an already functioning GMP-compliant laboratory producing clinical-grade MSC. Secondary end-points will help to evaluate the immunosuppressive potential of MSC after organ transplantation, and the opportunity to develop larger randomised, controlled, phase III trials. After successful transplantation, 10 liver and 10 kidney transplant recipients under standard immunosuppression (tacrolimus, MMF, steroids) will receive an intravenous infusion of 1.5-3x106/kg of third-party MSC on post-operative day 3±2. These patients will be prospectively compared to 10 liver and 10 kidney recipients who meet the inclusion criteria but deny MSC infusion. Safety will be assessed by recording side effects, including opportunistic infections and cancers. Immunosuppressive potential will be evaluated by rejection episode rates, by graft/patient survivals, by immunohistology of 3-months kidney and 6-month liver graft biopsies and by in vitro evaluation of the immunity profile of the recipients. In a second step, reduction (kidney) and progressive weaning (liver) of immunosuppression will be attempted in recipients who received MSC. This ongoing study is supported by research grants from the CHU of Liège, University of Liège, and by the Senior Clinical Research Grant from ESOT. The first patients were included and treated in early 2012, and final results expected in late 2013. [less ▲]

Detailed reference viewed: 107 (14 ULg)
Full Text
Peer Reviewed
See detailInfusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study
DETRY, Olivier ULg; VANDERMEULEN, Morgan ULg; DELBOUILLE, Marie-Hélène ULg et al

in Acta Gastro-Enterologica Belgica (2015, March), 78(1), 29

Background: Mesenchymal stromal cells (MSC) are multipotent bone marrow progenitors that have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aimed ... [more ▼]

Background: Mesenchymal stromal cells (MSC) are multipotent bone marrow progenitors that have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aimed to be the first evaluation of the safety and tolerability of MSC infusion after liver transplantation in a prospective, controlled phase-1 study. This study aimed to be the first evaluation of the safety and tolerability of MSC infusion after liver transplantation in a prospective, controlled phase-1 study. Patients & Methods: Clinical grade MSCs were locally collected from the bone marrow of unrelated healthy donors. They were cultured in a GMP-compliant lab, underwent extensive quality controls and were frozen for storage in a MSC bank. When needed for patient treatment, MSC were thawed and intravenously injected into patients. 10 liver transplant recipients under standard immunosuppression (TAC-MMF-low dose steroids until day 30) received 1.5-3x106/kg MSC on post-operative day 3±2. These patients were prospectively compared to a group of 10 control (MSC-) liver recipients. Primary endpoints were MSC infusion toxicity, and incidence of cancer and opportunistic infections at month 6. Secondary endpoints were patient and graft survivals and rejection at month 6, as well as the effects of MSC on recipients’ immune function and on immunohistology of at month 6 graft biopsies. Results: No MSC infusional toxicity was observed. Both groups were comparable in terms of donor and recipient characteristics. There was no difference in primary end-points between control and MSC groups. No patient developed de novo cancer. There was no statistical difference in patient and graft survivals or in rejection rates. There was no graft rejection in the MSC group. Month-6 graft biopsies were not different according to Banff and fibrosis scores. Discussion: This phase 1 study showed excellent tolerability and safety of a single infusion of third-party MSC after liver transplantation. There were no graft safety issues and no excess of immunosuppression after MSC injection. Further analyses of consequences of MSC injection on the immune profile are needed. The possibility of avoiding calcineurin-inhibitors with repeated MSC injections as main immunosuppressive therapy and/of tolerance induction by MSC infusion should be investigated by further studies. [less ▲]

Detailed reference viewed: 60 (2 ULg)
Full Text
Peer Reviewed
See detailInfusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study
DETRY, Olivier ULg; VANDERMEULEN, Morgan ULg; DELBOUILLE, Marie-Hélène ULg et al

in Transplant International (2015, November), 28(S4), 1027

Background: Mesenchymal stromal cells (MSC) are multipotent bone mar- row progenitors that have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aimed ... [more ▼]

Background: Mesenchymal stromal cells (MSC) are multipotent bone mar- row progenitors that have demonstrated significant immunosuppressive effects in various in vivo and in vitro studies. This study aimed to be the first evaluation of the safety and tolerability of MSC infusion after liver transplantation in a prospective, controlled phase-1 study. Methods: 10 liver transplant recipients under standard immunosuppression (TAC-MMF-low dose steroids until day 30) received 1.5–3 9 106/kg third party MSC on post-operative day 3 ` 2. These patients were prospectively compared to a group of 10 control liver recipients. Primary endpoints were MSC infusion toxicity, and incidence of cancer and opportunistic infections at month 6. Secondary endpoints were patient and graft survivals and rejection at month 6, as well as the effects of MSC on recipients’ immune function and on immunohistology of at month 6 graft biopsies. Results: No MSC infusional toxicity was observed. Both groups were comparable in terms of donor and recipient characteristics. There was no difference in primary end-points between control and MSC groups. No patient developed de novo cancer. There was no statistical difference in patient and graft survivals or in rejection rates. There was no graft rejection in the MSC group. Month-6 graft biopsies were not different according to Banff and fibrosis scores. Discussion: This phase 1 study showed excellent tolerability and safety of a single infusion of third-party MSC after liver transplantation. There were no graft safety issues and no excess of immunosuppression after MSC injection. Further analyses of consequences of MSC injection on the immune profile are needed. The possibility of avoiding calcineurin-inhibitors with repeated MSC injections as main immunosuppressive therapy and/of tolerance induction by MSC infusion should be investigated by further studies. This study is in part supported by an ESOT Senior Clinical Research Grant and by the University of Liege. [less ▲]

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailInfusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study
DETRY, Olivier ULg; VANDERMEULEN, Morgan ULg; DELBOUILLE, Marie-Hélène ULg et al

Poster (2015, March 27)

Transplanted patients have to deal with numerous side effects of life-long dependence on immunosuppressive drugs. Paradoxically these drugs fail to prevent acute and/or chronic rejection in many cases ... [more ▼]

Transplanted patients have to deal with numerous side effects of life-long dependence on immunosuppressive drugs. Paradoxically these drugs fail to prevent acute and/or chronic rejection in many cases. Mesenchymal stromal cells (MSC) are multipotent and self-renewing bone marrow progenitors that have been shown both in vitro and in vivo as capable of (i) immunomodulation, (ii) anti-inflammation in case of ischemia/reperfusion injury, and (ii) stimulation of tissue repair. MSC could therefore be very interesting in organ recipients to limit chronic graft damage and to allow tolerance. This study aimed to be the first clinical evaluation of the safety and tolerability of MSC infusion after liver transplantation in a prospective, controlled, phase I study. Clinical grade MSCs were locally collected from the bone marrow of unrelated healthy donors. They were cultured in a GMP-compliant lab, underwent extensive quality controls and were frozen for storage in a MSC bank. When needed for patient treatment, MSC were thawed and intravenously injected into patients. 10 liver transplant recipients under standard immunosuppression (TAC-MMF-low dose steroids until day 30) received 1.5-3x106/kg MSC on post- operative day 3 ± 2. These patients were prospectively compared to a group of 10 control (MSC-) liver recipients. Primary endpoints were MSC infusion toxicity, and incidence of cancer and opportunistic infections at month 6. Secondary endpoints were patient and graft survivals and rejection at month 6, as well as the effects of MSC on recipients’ immune function and on immunohistology of at month 6 graft biopsies. No MSC infusional toxicity was observed. Both groups were comparable in terms of donor and recipient characteristics. There was no difference in primary end-points between control and MSC groups. No patient developed de novo cancer. There was no statistical difference in patient and graft survivals or in rejection rates. There was no graft rejection in the MSC group. Month-6 graft biopsies were not different according to Banff and fibrosis scores. This phase I study showed excellent tolerability and safety of a single infusion of third-party MSC after liver transplantation. There were no graft safety issues and no excess of immunosuppression after MSC injection. Further analyses of consequences of MSC injection on the immune profile are needed. The possibility of avoiding calcineurin-inhibitors with repeated MSC injections as main immunosuppressive therapy and/of tolerance induction by MSC infusion should be investigated by further studies. [less ▲]

Detailed reference viewed: 37 (4 ULg)
Full Text
Peer Reviewed
See detail«‘Ingegno’, ‘giudizio’, ‘ambizione’. Ritratti di aristocratici fiorentini nelle Storie Fiorentine e nella Storia d'Italia»
Moreno, Paola ULg

in Moreno, Paola; Palumbo, Giovanni (Eds.) Francesco Guicciardini. Tra ragione e inquietudine. Actes du Colloque international. (2005)

Detailed reference viewed: 44 (5 ULg)
See detailIngénierie de formation en enseignement des langues
Lucchini, Silvia ULg

Scientific conference (2011)

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailIngénierie des ambiances urbaines: développement d'un dispositif pédagogique mixant approche numérique et créativité
Nguyen, Ngoc Luan ULg; Reiter, Sigrid ULg

Poster (2016)

Le présent poster décrit le dispositif pédagogique mis en œuvre pour accompagner les étudiants dans la conception et l’évaluation d’ambiances urbaines grâce à la combinaison d’un apprentissage par projet ... [more ▼]

Le présent poster décrit le dispositif pédagogique mis en œuvre pour accompagner les étudiants dans la conception et l’évaluation d’ambiances urbaines grâce à la combinaison d’un apprentissage par projet et de la modélisation numérique des projets développés à l’échelle du quartier. Cette activité de formation répond aux sept critères essentiels d’une situation-problème en apprentissage par projet. Ce poster résume l’expérience accumulée dans l’application de ce dispositif pédagogique innovant. [less ▲]

Detailed reference viewed: 30 (3 ULg)
See detailIngénierie des matériaux métalliques: Solidification des métaux et alliages - Traitement thermique
Lecomte-Beckers, Jacqueline ULg

Learning material (2008)

Solidification des métaux et alliages. Traitements thermiques et thermomécaniques des métaux et alliages. Corrosion des métaux. Traitements de surface.

Detailed reference viewed: 43 (0 ULg)
See detailIngéniérie des projets d'investissement
Corhay, Albert ULg; Mbangala, Mapapa ULg

Book published by Les Editions de l'Université de Liège (2010)

La décision d'investir naît de la nécessité ou de l'intérêt à réaliser un investissement. Ce dernier exige que l'investisseur prenne des décisions stratégiques qui engagent le projet pour de longues ... [more ▼]

La décision d'investir naît de la nécessité ou de l'intérêt à réaliser un investissement. Ce dernier exige que l'investisseur prenne des décisions stratégiques qui engagent le projet pour de longues périodes en mobilisant des ressources considérables de manière irréversible. Cela veut dire que lorsqu'un « porteur de projet » réalise un investissement, il renonce aujourd'hui à des ressources qui, investies dans un projet, devraient générer des gains futurs. Dans ce contexte, un investissement ne sera entrepris que si l'espérance des gains futurs est supérieure à l'investissement initial. Etant donné l'incertitude qui entoure les flux futurs et le nombre élevé des risques et d'obstacles liés au lancement d'une activité nouvelle, il est fortement recommandé de procéder à une évaluation financière des projets d'investissement. Cette étape revêt une grande importance puisqu'elle permet d'éclairer les décideurs sur les perspectives de rentabilité financière. Malheureusement, beaucoup de débutants la négligent avec des conséquences regrettables telles que l'abandon d'activités ou le dépôt de bilan, par exemple. Pourtant, il ressort de diverses études effectuées sur l'esprit d'entreprise qu'un entrepreneur bien préparé aura plus de chance de réussir que celui qui s'improvise. En somme, une bonne préparation peut éviter beaucoup d'erreurs et réduire les imprévus. Pour cela, il existe un certain nombre de critères susceptibles d'aider le décideur dans son choix. Parmi ces méthodes, on peut citer la valeur actualisée nette, le taux de rentabilité interne, le délai de récupération, etc. Ces méthodes ne constituent pas des remèdes miracles et doivent être utilement intégrées dans la stratégie globale du projet. Qui plus est, l'aboutissement heureux de tout projet d'investissement doit toujours être compris comme le résultat d'un « construit » par rapport à une situation de référence car il dépend de plusieurs facteurs dont notamment les motivations et les objectifs de l'investisseur, le secteur d'activité du projet, l'environnement dans lequel le projet s'inscrit, etc. Outre le projet d'investissement productif, on peut être amené à investir dans un actif financier (actions, obligations, contrats dérivés, ...). En effet, l'évolution économique de ces dernières années a fortement contribué au développement et à la popularité des marchés financiers et plusieurs investisseurs (particuliers, institutions, gouvernements) y recourent abondamment pour le placement des épargnes et de couverture des risques. Tout investisseur rationnel se doit de choisir le portefeuille de risque minimum pour un niveau de rendement espéré. Ce choix est lié au concept de la diversification qui consiste simplement pour un investisseur à ne pas investir tout dans un seul titre, mais à répartir ses investissements sur plusieurs titres, ce qui lui permet d'atteindre un meilleur rapport rendement/risque. Le modèle d'évaluation des actifs financiers fournit une estimation de valeur théorique d'un actif financier. [less ▲]

Detailed reference viewed: 309 (40 ULg)
Full Text
Peer Reviewed
See detailIngéniérie entre recherche et formation
Job, Pierre; Schneider-Gilot, Marguerite ULg

in Education et Didactique (in press)

Detailed reference viewed: 13 (1 ULg)
Full Text
See detailIngénierie génétique d'une β2-intégrine LFA-1 bovine résistante à la leucotoxine de Mannheimia haemolytica
Fett, Thomas ULg

Doctoral thesis (2012)

Domesticated bovines are known since decades to be prone to bacterial pneumonias. Among the causative agents, a consensus emerged stating that Mannheimia haemolytica is the most frequent bacterium ... [more ▼]

Domesticated bovines are known since decades to be prone to bacterial pneumonias. Among the causative agents, a consensus emerged stating that Mannheimia haemolytica is the most frequent bacterium isolated from bovine lungs throughout the world. Moreover, it appeared that its virulence specifically targets ruminant lungs in vivo and ruminant leucocytes in vitro. When the thesis was started, the two main actors underlying this species-specific virulence were known: the leukotoxin (LKT) on the pathogen side and the beta2-integrin LFA-1 on the host side. The objective of the thesis was to contribute to the understanding of the LKT/LFA 1 interaction at the molecular level. Using a between-species perspective, we showed that (i) the CD11a subunit of the LFA-1 heterodimer was not involved in the LKT-specificity for ruminant LFA-1, (ii) the EGF-3 module within the CD18 controls the susceptibility of any given CD18 to LKT and (iii) a non cleavable signal peptide conjugated to a LKT susceptible EGF-3-containing CD18 exacerbates LKT pronecrotic effects. [less ▲]

Detailed reference viewed: 88 (18 ULg)
See detailIngenierie genetique. Strategie et perspectives en agronomie.
Portetelle, Daniel ULg; Burny, A.; Hilger, F.

Book (1981)

Detailed reference viewed: 15 (1 ULg)